Scarica l'app Stockscreener
1.7507
4.33%
-0.0793
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations - Investing.com
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Innate Pharma Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts - Investing.com
Unusual VolumeStock ScreenerNews - Finviz
Innate Pharma reports interim lung cancer trial results By Investing.com - Investing.com South Africa
Innate Pharma reports interim lung cancer trial results - Investing.com
HC Wainwright Decreases Earnings Estimates for Innate Pharma - MarketBeat
Top GainersStock ScreenerSnapshot - Finviz
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com India
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - MarketBeat
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline By Investing.com - Investing.com India
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
NASDAQ New 52-Week Highs And Lows - Moomoo
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% – Here’s What Happened - Defense World
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference - ChartMill
Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2%Should You Sell? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Down 0.5%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3% – Should You Buy? - Defense World
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3%Should You Buy? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Up 3.7%Should You Buy? - MarketBeat
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress By Investing.com - Investing.com UK
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Should I buy Innate Pharma (IPHA) - Zacks Investment Research
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential By Investing.com - Investing.com South Africa
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Earnings call: Innate Pharma reports progress in drug development - Investing.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma (IPHA) Stock Forecast and Price Target 2026 - MarketBeat
Innate Pharma Announces Its Participation in Upcoming Investor Conference By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Which Is a Better Investment, Novo Nordisk A/S (ADR) or Sanofi SA (ADR) Stock? - AAII
Pluri (PLUR) Short Interest & Short Float | Updated May 2026 $PLUR - MarketBeat
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Conference Calls and Individual Investors - MarketBeat
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - The Chronicle-Journal
Which stocks are gapping on Tuesday? - ChartMill
Gapping stocks in Friday's session - ChartMill
What's going on in today's pre-market session - ChartMill
Unusual volume stocks in Thursday's session - ChartMill
Top movers in Tuesday's pre-market session - ChartMill
What's going on in today's after hours session - ChartMill
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):